These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 17299199)
1. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. Mahaffey KW; Harrington RA JAMA; 2007 Feb; 297(6):636-9. PubMed ID: 17299199 [No Abstract] [Full Text] [Related]
2. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD; JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194 [TBL] [Abstract][Full Text] [Related]
3. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
4. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Antman EM Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302 [TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML; Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255 [TBL] [Abstract][Full Text] [Related]
11. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines. Young JJ; Choo JK; Kereiakes DJ; ; J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626 [No Abstract] [Full Text] [Related]
12. [Glycoprotein IIb/IIIa antagonists]. Hennemann A Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193 [No Abstract] [Full Text] [Related]
13. Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond. Manoharan G; Adgey AA Heart; 2001 Sep; 86(3):259-61. PubMed ID: 11514474 [No Abstract] [Full Text] [Related]
14. Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization. Popma JJ Haemostasis; 1999 Dec; 29 Suppl S1():69-71. PubMed ID: 10629407 [TBL] [Abstract][Full Text] [Related]
15. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
20. Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-sT elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn. Bovenzi F; De Luca L J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):166-8. PubMed ID: 16645380 [No Abstract] [Full Text] [Related] [Next] [New Search]